CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acquisition of IMPATH validates this trend and promises to bring more change to …
New Competitors Line Up In Oncology Marketplace Read More »
